OneSource serves as the manufacturing partner and provides scale-up and commercial manufacturing of the formulation
Bangalore, April 30, 2026: OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that its partner Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.
The partnership is designed to ensure reliable and scalable commercial supply from OneSource’s US-FDA approved flagship manufacturing facility in Bengaluru.
Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”
Corporate Comm India (CCI Newswire)
